Form 4: Axsome Therapeutics Director Acquires Stock Options in Lieu of Cash Compensation

Director Susan Mahony acquired 1,312 stock options in Axsome Therapeutics in lieu of cash compensation on February 21, 2025.

Summary

• On February 21, 2025, Susan Mahony, a director of Axsome Therapeutics, acquired 1,312 stock options.
• These options were received in lieu of cash compensation earned in 2024.
• The exercise price of the options is $137.75.
• The options are immediately exercisable and expire on February 20, 2035.
• Following the transaction, Mahony directly owns 1,312 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options to a director is a common practice and can be seen as a positive sign of alignment with shareholder interests. There are no explicit negative indicators.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
• The options being immediately exercisable provides the director with immediate potential benefit from any increase in the company's stock price.

Industry Context

This is a standard practice for compensating board members and executives, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a common practice in the pharmaceutical industry to incentivize performance and align their interests with shareholders.
• Companies like Biogen and Amgen also use stock options as part of their compensation packages for directors.
• The specific number of options and exercise price would need to be compared to similar companies to determine if it is within industry norms.

Stakeholder Impact

• Shareholders may view the granting of stock options to a director as a positive sign, aligning the director's interests with their own.
• Employees may see this as a sign of confidence in the company's future.

Key Dates